阿杜那单抗相关淀粉样蛋白相关影像学异常:赞歌还是悲歌?
本文针对FDA基于淀粉样蛋白PET显示的剂量依赖性脑淀粉样蛋白沉积减少而加速批准阿杜那单抗提出质疑,认为该批准偏离了保证药物安全有效的使命。作者认为淀粉样蛋白PET所见的淀粉样蛋白沉积减少反映的是阿杜那单抗治疗导致的脑细胞死亡增加,因此随时间推移应预期治疗患者病情恶化而非改善。
要点
- FDA基于淀粉样蛋白PET显示的剂量依赖性淀粉样蛋白沉积减少加速批准阿杜那单抗,而非基于已证实的临床疗效。
- 作者认为淀粉样蛋白PET所见的淀粉样蛋白沉积减少反映阿杜那单抗治疗导致的脑细胞死亡增加。
- 作者认为随时间推移应预期治疗患者病情恶化而非改善。
核心结论
- 作者认为FDA加速批准阿杜那单抗偏离了保证药物安全有效的使命,因批准仅基于淀粉样蛋白PET所见的剂量依赖性脑淀粉样蛋白沉积减少而非已证实的临床疗效。
- 作者认为淀粉样蛋白PET所见的淀粉样蛋白沉积减少反映阿杜那单抗治疗导致的脑细胞死亡增加,随时间推移应预期治疗患者病情恶化而非改善。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
When the FDA granted accelerated approval of Biogen's Alzheimer disease drug, aducanumab (marketed as Aduhelm), it deviated from its mission of guaranteeing drug safety and efficacy because the approval was based exclusively on a perceived dose-dependent reduction in brain amyloid deposits and not upon a proven clinical effect. We believe that the amyloid-PET scans, perceived as showing decreasing amyloid deposits, are an expression of increased cerebral cell death due to aducanumab treatment, so that with time one should instead expect a worsening and not an improvement in the treated patients' condition.
引用
- Høilund-Carlsen PF, Werner TJ, Alavi A, et al. Aducanumab-Related Amyloid-Related Imaging Abnormalities: Paean or Lament? Clin Nucl Med. 2022. PMID: 35452007. doi:10.1097/RLU.0000000000004250
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。